New stent aims to keep multiple heart arteries open

NCT ID NCT06168305

ENROLLING_BY_INVITATION Disease control Sponsor: Genoss Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 1000 adults with multivessel coronary artery disease who received a special drug-coated stent called GENOSS® DES. The stent slowly releases sirolimus to help prevent the artery from narrowing again. Researchers are monitoring safety and effectiveness over time, including heart-related deaths, heart attacks, and the need for repeat procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sirolimus-eluting coronary stent (GENOSS® DES)
What this could lead to: If successful, this could confirm that the GENOSS® DES stent is a safe and effective option for people with blockages in multiple heart arteries.
What could go wrong: This is an observational study, not a randomized trial, so results may be less definitive. Stents carry risks like blood clots or re-narrowing, and long-term outcomes are still being tracked.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIVESSEL CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIVESSEL CORONARY ARTERY DISEASE PERCUTANEOUS CORONARY INTERVENTION

Contacts and locations

Locations

Korea University GURO Hospital

Seoul, Seoul, 08308, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.